Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
P/E Ratio
--
P/B Ratio
2.42
Industry P/E
--
Debt to Equity
0
ROE
-5.32 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.28
CFO
$-35.06 Mln
EBITDA
$-54.51 Mln
Net Profit
$-72.22 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ABVC Biopharma Inc (ABVC)
| 42.56 | 21.90 | 61.75 | -19.13 | -67.54 | -51.70 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
ABVC Biopharma Inc (ABVC)
| -48.86 | -81.44 | -81.56 | -33.53 | 16.70 | -99.33 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy... for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation. Address: 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538 Read more
Chairman & Chief Business Officer
Mr. Eugene Jiang
Chairman & Chief Business Officer
Mr. Eugene Jiang
Headquarters
Fremont, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ABVC Biopharma Inc (ABVC) stood at $ 21 Mln as on 30-Sep-24
The share price of ABVC Biopharma Inc (ABVC) is $0.84 (NASDAQ) as of 23-Apr-2025 14:39 EDT. ABVC Biopharma Inc (ABVC) has given a return of -67.54% in the last 3 years.
ABVC Biopharma Inc (ABVC) has a market capitalisation of $ 21 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ABVC Biopharma Inc (ABVC) is 2.42 times as on 22-Apr-2025, a 10% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of ABVC Biopharma Inc (ABVC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ABVC Biopharma Inc (ABVC) and enter the required number of quantities and click on buy to purchase the shares of ABVC Biopharma Inc (ABVC).
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation. Address: 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
The CEO & director of Mr. Eugene Jiang. is ABVC Biopharma Inc (ABVC), and CFO & Sr. VP is Mr. Eugene Jiang.
There is no promoter pledging in ABVC Biopharma Inc (ABVC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| ABVC Biopharma Inc (ABVC) | Ratios |
|---|---|
|
Return on equity(%)
|
-94.88
|
|
Operating margin(%)
|
-1252.56
|
|
Net Margin(%)
|
-1616.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ABVC Biopharma Inc (ABVC) was $0 Mln.
$0.01
(
